Organization | Altimmune, Inc.

Altimmune, Inc. Report issue

For profit Phase 1 Phase 2 Phase 4

Founded: Gaithersburg MD United States (1997)

Organization Overview

First Clinical Trial

2008

NCT00755703

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2022

Timeline

NOW

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Altimmune, Inc.

Active Ingredients

Drugs in Phase 4 Trials (1)

Key: Altimmune, Inc. (0) Acquired (1)

inactivated influenza vaccine (3 trials)

Drugs in Phase 2 Trials (7)

Key: Altimmune, Inc. (4) Acquired (3)

alt-801 (6 trials)

aluminum hydroxide (Gaviscon) (3 trials)

fp-01.1 (4 trials)

heptcell (1 trial)

nasovax (2 trials)

pemvidutide (1 trial)

rpa102 (2 trials)

Drugs in Phase 1 Trials (17)

Key: Altimmune, Inc. (11) Acquired (6)

adcovid (1 trial)

anthrax vaccine, adsorbed (Biothrax) (1 trial)

atorvastatin (lipitor) (1 trial)

butyrlcholinesterase, human (Recombinant) (Protexia) (1 trial)

ciprofloxacin (cipro) (1 trial)

digoxin (lanoxin) (1 trial)

doxycycline (vibramycin) (1 trial)

ethinyl estradiol (Estinyl) (1 trial)

fp-02.2 (1 trial)

ic31 (1 trial)

levonorgestrel (1 trial)

mdx-1303 (Valortim) (4 trials)

metformin (glucophage) (1 trial)

nasoshield (2 trials)

rf1v vaccine (1 trial)

sodium chloride (1 trial)

warfarin (coumadin) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Adenoviridae Infections (Phase 1)

Communicable Diseases (Phase 2)

Coronavirus Infections (Phase 2)

Fatty Liver (Phase 1)

Hepatitis (Phase 2)

Hepatitis A (Phase 2)

Hepatitis B (Phase 2)

Hepatitis B, Chronic (Phase 2)

Infections (Phase 2)

Influenza, Human (Phase 4)

Non-alcoholic Fatty Liver Disease (Phase 1)

Overweight (Phase 1)

Severe Acute Respiratory Syndrome (Phase 2)

Overview

Highest Phase: Phase 2
# of Trials: 28
# of Trial APIs: 25